Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (1) · (multiple, generic dominant) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Temovate, Clobex, Cormax, Olux, Olux-E, Impoyz (1)

2C-x series (1) · Analgesic (2) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychedelic (1) · super-potent)]] (1) · [[:Category:Corticosteroids|Corticosteroid]] (1) · [[:Category:Glucocorticoids|Glucocorticoid]] (1) · [[:Category:Topical_corticosteroids|Topical corticosteroid (Class I (1)

None (1) · 5-HT2A partial agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-0000079C-QINU`"', '"`UNIQ--vote-0000079D-QINU`"' (1)

None (2) · Adult: 15–60 mg every 4 hours as needed. (1) · Apply a thin film to affected area BID; '''limit to 2 weeks''' continuous use and ≤50 g/week (cream/ointment); ≤50 mL/week (foam/solution); avoid face, intertriginous areas (1)

None (2) · Cream, ointment, lotion, foam, solution, shampoo, spray at 0.025-0.05%; emollient and non-emollient bases (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (2) · 360 mg/day (1) · 50 g/week (cream/ointment); 2-week continuous limit; 4-week maximum cumulative (1)

None (1) · insufflated (1) · Oral (1) · PO (only formulation marketed in the US). (1) · PR (1) · Topical (1)

None (1) · 30–60 min (PO) (1) · 45-75 min (oral) (1) · Hours to days for inflammation; substantial improvement within 1 week (1)

None (1) · 4-8 h (1) · 4–6 hours (1) · Hours to days per application (1)

None (1) · 2.5–3 hours (1) · Not meaningfully described for topical use (systemic exposure varies with surface area, occlusion, skin integrity)'"`UNIQ--ref-0000079E-QINU`"' (1) · Not well characterized (1)

None (1) · Not well characterized (1) · Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas'"`UNIQ--ref-0000079F-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Not established (1) · Topical corticosteroids in pregnancy: use lowest potency and smallest area; super-potent agents like clobetasol are reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

None (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (1)